iDD biotech Enters Worldwide Exclusive Licence Concerning Antibodies and Patents Related to CK8


CK8 is expressed at the cell surface in cancer cells , in particular in colon cancer but also in head and neck carcinoma, in glioma as well as in lung cancers. iDD biotech, together with Lyon Cancer Research Center , hosted by the Centre Leon Berard , has developed humanized MAb targeting eCK8 and has gained spectacular in-vivo POC with tumour shrinkage and massive necrosis.



from Biotech News